Examinando por Autor "Duran, Pablo"
Mostrando 1 - 4 de 4
Resultados por página
Opciones de ordenación
Ítem Exploring the links between Obesity and Psoriasis: A comprehensive review(MDPI, 2022) Barros, Gabriela; Duran, Pablo; Vera, Ivana; Bermúdez, ValmoreObesity is a major public health issue worldwide since it is associated with the development of chronic comorbidities such as type 2 diabetes, dyslipidemias, atherosclerosis, some cancer forms and skin diseases, including psoriasis. Scientific evidence has indicated that the possible link between obesity and psoriasis may be multifactorial, highlighting dietary habits, lifestyle, certain genetic factors and the microbiome as leading factors in the progress of both pathologies because they are associated with a chronic pro-inflammatory state. Thus, inflammation management in obesity is a plausible target for psoriasis, not only because of the sick adipose tissue secretome profile but also due to the relationship of obesity with the rest of the immune derangements associated with psoriasis initiation and maintenance. Hence, this review will provide a general and molecular overview of the relationship between both pathologies and present recent therapeutic advances in treating this problem.Ítem Hypertension, emotions and happiness: A brief view from the biology to the positive psychology(Saber UCV, Universidad Central de Venezuela, 2022) Bautista-Sandoval, María; Chacín, Maricarmen; Chaparro-Suárez, Yudy; Riaño-Garzón, Manuel E; Díaz-Camargo, Edgar Alexis; Duran, Pablo; Parra, Heliana; Castro, Ana; Nava, Manuel; Medina Ortiez, Oscar; D’Marco, Luis; Rojas, Edward; Bermúdez, ValmoreHigh blood pressure (HBP) is a silent disease with an extremely high prevalence worldwide. It is considered the leading risk factor for cardiovascular (CVD) and neurovascular disorders. The etiology of hypertension is based on various genetic, environmental, and social factors. Currently, compelling evidence points to the link between HBP and certain psycho-emotional factors, such as mental stability, happiness, general well-being, and fulfillment, all consistently associated with better physical and psychological health. Clinical and epidemiological evidence supports their value as a novel target in HBP management despite the lack of clarity concerning how psycho-emotional and affective states affect cardiovascular health. Among the main psycho-emotional strategies implemented to treat HBP and other CVD patients, emphasis should be placed on psychosocial interventions and positive psychology, which have shown promising results in this regard thus far. Therefore, this review aims to comprehensively determine whether an individual’s psychosocial and emotional state can be an HBP risk factor.Ítem Lipid Accumulation Product Is More Related to Insulin Resistance than the Visceral Adiposity Index in the Maracaibo City Population, Venezuela(Hindawi, 2021) Bermúdez, Valmore; Salazar, Juan; Fuenmayor, Jorge; Nava, Manuel; Ortega, Ángel; Duran, Pablo; Rojas, Milagros; Añez, Roberto; Rivas-Montenegro, Alejandra; Angarita, Lissé; Chacín, Maricarmen; Cano, ClímacoBackground. Visceral adiposity is related to insulin resistance (IR), a metabolic state considered as a risk factor for other cardiometabolic diseases. In that matter, mathematical indexes such as the visceral adiposity index (VAI) and the lipid accumulation product (LAP) could indirectly assess IR based on visceral adiposity. Objective. To evaluate the association and diagnostic accuracy of VAI and LAP to diagnose IR in the adult population of Maracaibo city. Methods. This is a cross-sectional descriptive study with multistage sampling. Receiver operating characteristic (ROC) curves were built to determine VAI and LAP cutoff points to predict IR. A set of logistic regression models was constructed according to sociodemographic, psychobiologic, and metabolic variables. Results. 1818 subjects were evaluated (51.4% women). The area under the curve (AUC) values for LAP and VAI were 0.689 (0.665–0.714) and 0.645 (0.619–0.670), respectively. Both indexes showed a higher IR risk in the upper tertile in bivariate analysis. However, in the logistic regression analysis for the IR risk, only the 2nd (OR: 1.91; 95% CI: 1.37–2.65; ) and 3rd (OR: 5.40; 95% CI: 3.48–8.39; ) LAP tertiles showed a significant increase. This behaviour was also observed after adjusting for hs-C-reactive protein (hs-CPR). Conclusion. Although both indexes show a low predictive capacity in individuals with IR in the Maracaibo city population, the LAP index was more strongly associated with IR.Ítem Specialized Pro-Resolving Lipid Mediators: The Future of Chronic Pain Therapy?(MDPI, 2021) Chávez-Castillo, Mervin; Ortega, Ángel; Cudris-Torres, Lorena; Duran, Pablo; Rojas, Milagros; Manzano, Alexander; Garrido, Bermary; Salazar, Juan; Silva, Aljadis; Rojas-Gomez, Diana Marcela; De Sanctis, Juan B.; Bermúdez, ValmoreChronic pain (CP) is a severe clinical entity with devastating physical and emotional consequences for patients, which can occur in a myriad of diseases. Often, conventional treatment approaches appear to be insufficient for its management. Moreover, considering the adverse effects of traditional analgesic treatments, specialized pro-resolving lipid mediators (SPMs) have emerged as a promising alternative for CP. These include various bioactive molecules such as resolvins, maresins, and protectins, derived from ω-3 polyunsaturated fatty acids (PUFAs); and lipoxins, produced from ω-6 PUFAs. Indeed, SPMs have been demonstrated to play a central role in the regulation and resolution of the inflammation associated with CP. Furthermore, these molecules can modulate neuroinflammation and thus inhibit central and peripheral sensitizations, as well as long-term potentiation, via immunomodulation and regulation of nociceptor activity and neuronal pathways. In this context, preclinical and clinical studies have evidenced that the use of SPMs is beneficial in CP-related disorders, including rheumatic diseases, migraine, neuropathies, and others. This review integrates current preclinical and clinical knowledge on the role of SPMs as a potential therapeutic tool for the management of patients with CP.